The BioPharm Brief: Survival, Scrutiny, and a Setback

Sep 09, 08:01 PM
Headliner
Share
Subscribe

Today’s BioPharm Brief looks at a phase 3 survival win for Imdelltra plus Imfinzi in first-line small cell lung cancer, FDA review of Rezolute’s ersodetug, and Novartis’s del-desiran setback in myotonic dystrophy type 1.

Share
Subscribe
Next
The BioPharm Brief: Delivery, Priority, and Gene Therapy
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief